Another form of PFIC, PFIC type 2, is characterised by persistent neonatal cholestasis with histological features of neonatal hepatitis and later biliary cirrhosis. Serum bile acid concentrations and alkaline phosphatase activities are elevated and the serum GT activity is normal. Strautnieks et al suggest that the gene defect for this disease is located in a locus at chromosome 2q24, the FIC2 locus. 7 This disease probably also results from a defect of hepatobiliary bile salt transport. A recently cloned candidate protein for the canalicular bile salt transporter belongs to the P-glycoprotein family and is called "the sister of P-glycoprotein". Interestingly this protein is encoded by a gene on chromosome 2q24.
de Vree and associates have characterised a third type of PFIC, PFIC type 3. This disease presents with recurrent pruritus or jaundice in the first months of life and then progresses to biliary cirrhosis. In contrast to patients with PFIC types 1 or 2, these patients have a high serum GT activity. Oude Elferink's and Borst's groups have been involved in the development of the mdr2 knockout mouse. 8 In this model there is no phospholipid transport from liver to bile. Mdr2 in rodents, known as MDR3 in humans, has been characterised as a phospholipid translocator, mediating the transfer of phosphatidylcholine from the inner leaflet of the canalicular membrane to the outer leaflet. 9 A functional bile salt transporter is needed for the transfer of phospholipids from the membrane into the bile as the extraction of phospholipids from the canalicular membrane is mediated by bile salts. 10 Mdr2 knockout mice produce bile in which phospholipids are low to absent and the bile salt concentration is normal. As reported earlier by De Leuze et al, patients with PFIC type 3 also produce bile salt containing bile without phospholipids. 11 The histological abnormalities of these patients and the knockout mice are remarkably similar. They consist of periportal inflammation, extensive bile duct proliferation, feathery degeneration of hepatocytes, fibrosis and, in the knockout mice, liver malignancy. The hypothesis is that this histological picture results from the cytotoxicity of bile salts which in normal bile is antagonised by phospholipids.
The two patients described by de Vree et al lack MDR3 in the liver. RT-PCR revealed homozygous mutations in the MDR3 mRNA. Genomic DNA analysis of their parents showed that they are heterozygous for this mutation. A sister of one of the patients is homozygous normal and so does not have the disease. It is interesting that the mother of one of these patients had recurrent episodes of cholestasis during pregnancy, suggesting that the heterozygous state may be associated with this condition. Neither of the patients responded to treatment with ursodeoxycholic acid (UDCA). The authors speculate that patients with the complete MDR3 defect do not respond to UDCA whereas those who do (about 50% with this disease) have a partial defect.
Will the patients or their families benefit from these findings? One positive outcome is that prenatal diagnosis in families with an aVected child is now potentially possible. As for gene therapy, it is too early to speculate but a reasonable idea is that diseases which have with a recurrent disease pattern, such as PFIC-1 and PFIC-3, may be amenable to gene therapy if the functional gene can be given before the liver becomes too cirrhotic. Finally, PFIC-2 and PFIC-3 are probably true liver diseases as the proposed molecular defects aVect proteins which are expressed predominantly in the liver. PFIC-1 is thought to be caused by a defective protein which resides in the liver and which is even more highly expressed in the intestine. Liver transplantation in patients with PFIC-1 may only be partly corrective; persistent diarrhoea has indeed been reported in transplanted children with this disease. 
